Molnupiravir is an investigational oral antiviral medicine that was given to “at risk” patients who have mild to moderate COVID symptoms. The “at risk” patients in the study had at least one risk factor for severe COVID leading to hospitalization or death.
Since the trial started in August, these are the results:
Patients who received molnupiravir = 385
Hospitalized = 28 or 7%
Died = none
Patients who received placebo = 377
Hospitalized = 53 or 14%
Died = 8 people
http://www.emilypostnews.com/p/merck-covid-pill-makes-moderna-vaccine
| 
